Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study

BACKGROUND: Preoperative 5-FU-based chemoradiation is currently a standard treatment for advanced rectal cancer, particularly in Western countries. Although it reduced the local recurrence, it could not necessarily improve overall survival. Furthermore, it can also produce adverse effects and long-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizushima, Tsunekazu, Ikeda, Masataka, Kato, Takeshi, Ikeda, Atsuyo, Nishimura, Junichi, Hata, Taishi, Matsuda, Chu, Satoh, Taroh, Mori, Masaki, Doki, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751668/
https://www.ncbi.nlm.nih.gov/pubmed/31533662
http://dx.doi.org/10.1186/s12885-019-6122-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751668/
https://www.ncbi.nlm.nih.gov/pubmed/31533662
http://dx.doi.org/10.1186/s12885-019-6122-2

Ejemplares similares